SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.63), $0.21 worse than the analyst estimate of ($2.42).

Guidance:

• Based on its current operating plan, Sage anticipates that its existing cash, cash equivalents and marketable securities as of September 30, 2018 will enable Sage to fund its operating expenses and capital expenditure requirements into 2020.
• Sage expects that its operating expenses will increase year-over-year in 2018 to support continued pipeline advancement, including ongoing Phase 3 development of SAGE-217, and potential commercialization of ZULRESSO in PPD, if approved

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.